deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT06732960

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients (LIGHT)

A Randomized, Double-Blind, Placebo-controlled Study of Efsubaglutide Alfa on Weight Management in Subjects With Overweight or Obesity to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy.

Sponsor: Beijing Friendship Hospital

Conditions Overweight or Obesity
Interventions Efsubaglutide Alfa Placebo
Updated 2 times since 2025 Last updated: Apr 1, 2025 Started: Apr 21, 2024 Primary completion: Nov 18, 2024 Completion: Nov 18, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Overweight or Obesity and is currently completed. Beijing Friendship Hospital leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2025 – ~May 2025 · 4 months · monthly snapshotActive Not Recruiting~May 2025 – present · 16 months · monthly snapshotCompleted

Change History

2 versions recorded

  1. May 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Friendship Hospital
  • Jinan Central Hospital
  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital
  • Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Data source: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations